

CORRECTION

In the article, “ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction),” by Krumholz et al., which appeared in the January 3, 2006, issue of the journal (*J Am Coll Cardiol* 2006;47:236–65), the following corrections are needed:

1. Table 10 (p. 256): In the entry for “Denominator,” the phrase “who received fibrinolytic therapy or primary percutaneous intervention (PCI)” should be deleted so that it reads “AMI patients with ST-elevation on ECG.”
2. In APPENDIX D (p. 261), the relationships with industry information for Dr. Eugene Braunwald is as follows.

Reviewer Name†	Representation	Research Grant	Speakers Bureau/Honoraria	Stock Ownership	Consultant/Advisory Board
Dr. Eugene Braunwald	<ul style="list-style-type: none"> • Content Reviewer—ACC/AHA UA/NSTEMI Guideline Writing Committee Chair 	<ul style="list-style-type: none"> • Astra Zeneca • Sanofi-Aventis • CV Therapeutics • Eli Lilly • Millennium • Schering Plough • Nuvelo • Pfizer • Inotek • Merck • Bristol-Myers Squibb 	<ul style="list-style-type: none"> • Astra Zeneca • Sanofi-Aventis • CV Therapeutics • Eli Lilly • Millennium • Schering Plough • Nuvelo • Pfizer • Inotek • Merck • Bristol-Myers Squibb 	None	<ul style="list-style-type: none"> • Momenta • Scios • Biopure • Sanofi/Synthelabo • Schering-Plough • Bristol-Myers Squibb • Pfizer • Interleuken Genetics • Protein Design Labs • Bayer, Ag

doi:10.1016/j.jacc.2006.04.011